Literature DB >> 22347886

Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin.

Carlos Marques Candeias1, Inês Luís, Joana Ribeiro, Luís Costa, Luís Soares de Almeida, Manuel Marques Gomes, Luísa Barreto, Luís Brito-Avô, José Luís Ducla-Soares.   

Abstract

Angiosarcoma is the most common primary malignant tumour of the heart. It is a rare and aggressive neoplasm that almost always has a short and fatal evolution. By the time it produces symptoms it has usually progressed to a mass causing haemodynamic compromise. Initial presentation with metastatic disease is unusual. We report the case of a 72-year-old man who presented with painful skin lesions on both hands. The skin biopsy was diagnosed as intravascular metastasis of epithelioid angiosarcoma. Body computed tomography scan disclosed a solid mass in the left atrium. The tumour was judged unresectable and the patient was treated with systemic chemotherapy, consisting of liposomal doxorubicin, which resulted in a complete clinical response. The patient remains free of disease after 48 months of follow-up. The excellent clinical evolution of our patient verifies that liposomal doxorubicin may be effective in the treatment of these tumours and significantly prolong patients' lifespan.

Entities:  

Year:  2010        PMID: 22347886      PMCID: PMC3027499          DOI: 10.1136/bcr.08.2009.2157

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Primary cardiac sarcomas.

Authors:  J B Putnam; M S Sweeney; R Colon; L A Lanza; O H Frazier; D A Cooley
Journal:  Ann Thorac Surg       Date:  1991-06       Impact factor: 4.330

2.  Primary sarcomas of the heart.

Authors:  A P Burke; D Cowan; R Virmani
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

3.  Cardiac epithelioid angiosarcoma presenting as cutaneous metastases.

Authors:  J F Val-Bernal; J Figols; F P Arce; J Sanz-Ortiz
Journal:  J Cutan Pathol       Date:  2001-05       Impact factor: 1.587

4.  Cardiac angiosarcoma responding to multidisciplinary treatment.

Authors:  S Kakizaki; H Takagi; Y Hosaka
Journal:  Int J Cardiol       Date:  1997-12-19       Impact factor: 4.164

5.  Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).

Authors:  S Toma; A Tucci; G Villani; G Carteni; N Spadini; R Palumbo
Journal:  Anticancer Res       Date:  2000 Jan-Feb       Impact factor: 2.480

6.  Cardiac angiosarcoma: an unusual presentation with cutaneous metastases.

Authors:  G J Pomper; R Gianani; R J Johnston; M N Rizeq
Journal:  Arch Pathol Lab Med       Date:  1998-03       Impact factor: 5.534

7.  Improved outcome with multimodality therapy in primary cardiac angiosarcoma.

Authors:  Courtney Pigott; Michael Welker; Pam Khosla; Robert S D Higgins
Journal:  Nat Clin Pract Oncol       Date:  2008-02

8.  Cardiac sarcomas presenting as metastatic disease.

Authors:  M J Herhusky; S B Gregg; R Virmani; P K Chun; H Bender; G F Gray
Journal:  Arch Pathol Lab Med       Date:  1985-10       Impact factor: 5.534

Review 9.  Angiosarcoma. A report of 67 patients and a review of the literature.

Authors:  R J Mark; J C Poen; L M Tran; Y S Fu; G F Juillard
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

10.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors:  D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more
  1 in total

Review 1.  Vascular sarcomas.

Authors:  Vinod Ravi; Shreyaskumar Patel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.